An adenoviral-based immunotherapy improved disease-free survival in men with localized intermediate- or high-risk disease, but experts had reservations.
Primary prevention in PCa still represents an unmet need, given the lack of certain preventive measures, notwithstanding the large number of studies on the subject [11]. Emerging evidence suggests ...
Novel prostate cancer treatment can reduce risk of disease progression by half, clinical trial shows
A Phase III clinical trial led by Neeraj Agarwal, MD, FASCO, senior director of clinical research at Huntsman Cancer Institute and professor of internal medicine at the University of Utah (the U), has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results